Subtype
Throat Carcinoma
CI-CAN-00006917Explore in graph →
369 active trials1 approved drugs2 evidence items
- NCIt
- C35506
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006917Explore in graph →
Clinical trials
1,035 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (87)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04945421 | IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC | completed | Phase 1 | 30 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Feb 23, 2023 | clinicaltrials |
| NCT04813705 | 18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma | recruiting | Phase 2 | 93 | Taizhou HospitalOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC |
| unknown |
| Phase 2 |
| 32 |
| Sun Yat-sen UniversityOTHER |
| 1 |
| Feb 13, 2023 |
| clinicaltrials |
| NCT05549466 | Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC | unknown | Phase 2 | 84 | Sun Yat-sen UniversityOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05717764 | Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment | not yet recruiting | Phase 3 | 500 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.INDUSTRY | 0 | Feb 8, 2023 | clinicaltrials |
| NCT05717790 | Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma | recruiting | N/A | 288 | Fourth Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT04405622 | Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. | unknown | Phase 2 | 21 | Sun Yat-sen UniversityOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05707819 | Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma | recruiting | — | 43 | Cancer Hospital of Guangxi Medical UniversityOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT05568641 | Vitamin-D Receptor in Laryngeal Squamous Cell Carcinoma | unknown | — | 50 | Sohag UniversityOTHER | 0 | Jan 18, 2023 | clinicaltrials |
| NCT04350190 | Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | completed | Phase 2 | 25 | Wei JiangOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT05682703 | A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Nasopharyngeal Carcinoma. | unknown | — | 2,000 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT05679856 | Vocal Cord vs Whole Laryngeal Radiotherapy for T1aN0 Glottic Cancer(VC-Larynx) | unknown | N/A | 50 | National Cancer Institute, EgyptOTHER | 1 | Jan 11, 2023 | clinicaltrials |
| NCT05674305 | Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy | recruiting | Phase 3 | 366 | Fudan UniversityOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT03032250 | Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer | completed | N/A | 35 | Wake Forest University Health SciencesOTHER | 1 | Jan 9, 2023 | clinicaltrials |
| NCT05512767 | A Pneumatic Compression Device for the Treatment of Lymphedema in Patients With Stage II-IV Head and Neck Cancer After Chemoradiation | withdrawn | N/A | 0 | Mayo ClinicOTHER | 0 | Jan 6, 2023 | clinicaltrials |
| NCT05654077 | EBV CAR-T Cells for Nasopharyngeal Carcinoma | unknown | Early Phase 1 | 24 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Dec 19, 2022 | clinicaltrials |
| NCT05616468 | BGT007 Cell Treatment of Nasopharyngeal Carcinoma | unknown | Early Phase 1 | 23 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05652192 | SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC | recruiting | Phase 2 | 37 | Zhejiang Cancer HospitalOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05061940 | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols. | terminated | — | 22 | Repertoire Immune MedicinesINDUSTRY | 1 | Dec 6, 2022 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT05627310 | Development and Validation of a Deep Learning System for Nasopharyngeal Carcinoma Using Endoscopic Images | unknown | — | 50,000 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT01855451 | Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma(HPVOropharynx) | unknown | Phase 3 | 189 | Trans Tasman Radiation Oncology GroupOTHER | 2 | Nov 18, 2022 | clinicaltrials |
| NCT05622474 | A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy | not yet recruiting | N/A | 236 | Sun Yat-sen UniversityOTHER | 1 | Nov 18, 2022 | clinicaltrials |
| NCT05415098 | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | unknown | Phase 1 | 90 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Nov 16, 2022 | clinicaltrials |
| NCT05611515 | Treatment of Early Supraglottic Squamous Cell Carcinoma With Advance Technologies(SUPRA-QoL) | recruiting | — | 108 | Centre Hospitalier Universitaire UCLouvain NamurOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT01088802 | Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx | completed | Phase 2 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT03837808 | Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma | unknown | Phase 3 | 384 | Sun Yat-sen UniversityOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT04636632 | Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma | completed | Phase 1 | 100 | Sun Yat-sen UniversityOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT02460419 | Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma | completed | Phase 3 | 104 | Sun Yat-sen UniversityOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT00274937 | Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer | completed | Phase 3 | 111 | Children's Oncology GroupNETWORK | 3 | Oct 25, 2022 | clinicaltrials |
| NCT00188253 | Positron Emission Tomography Scanning and Epstein-Barr Virus DNA Levels in the Staging and Follow-up of Nasopharyngeal Carcinoma. | completed | — | 30 | University Health Network, TorontoOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT02063399 | Prospective Nasopharyngeal Carcinoma Screening Using Plasma Epstein-Barr Virus DNA Analysis | unknown | — | 20,302 | Chinese University of Hong KongOTHER | 1 | Oct 17, 2022 | clinicaltrials |
| NCT01891695 | OPSCC N0 Nodal Control With Reduced IMRT | terminated | N/A | 1 | Paul W. Read, MDOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT02002182 | ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer | completed | Phase 2 | 15 | Andrew SikoraOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT05547971 | Development of Intelligent Model for Radioactive Brain Damage of Nasopharyngeal Carcinoma Based on Radio-metabolomics | unknown | — | 800 | Xiangya Hospital of Central South UniversityOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT05519956 | Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International Guidelines | unknown | Phase 3 | 398 | Fujian Cancer HospitalOTHER_GOV | 0 | Sep 19, 2022 | clinicaltrials |
| NCT03448341 | Dysphagia Assessment After Swallowing Sparing RadioTherapy(DASRT) | completed | — | 74 | Azienda Ospedaliero, Universitaria PisanaOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT05514275 | Radiotherapy Combined With Endostatin and Capecitabine for NPC | recruiting | Phase 2 | 41 | Zhejiang Cancer HospitalOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT01265849 | Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity(IT-MATTERS) | completed | Phase 3 | 928 | CEL-SCI CorporationINDUSTRY | 23 | Aug 19, 2022 | clinicaltrials |
| NCT03148665 | Saliva-based Detection of CD44(Detect 44) | completed | — | 85 | Joseph CalifanoOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT04898374 | Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma | unknown | Phase 3 | 120 | Kuwait Cancer Control CenterOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT05503914 | Low-dose Radiotherapy and Neoadjuvant Chemotherapy Sequential Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma | unknown | N/A | 80 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT05397769 | Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial. | recruiting | Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT04831450 | Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) | withdrawn | Phase 2 | 0 | University of MiamiOTHER | 0 | Aug 4, 2022 | clinicaltrials |
| NCT05484375 | Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment | not yet recruiting | Phase 2 | 40 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 0 | Aug 2, 2022 | clinicaltrials |
| NCT04001413 | Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT00470496 | Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer | completed | Phase 1 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT03121716 | A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects | completed | Phase 1 | 23 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT05447169 | Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening | recruiting | — | 11,625 | Sun Yat-sen UniversityOTHER | 1 | Jul 8, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Feb 23, 2023source: clinicaltrials